Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 02 January 2026

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1769802

Correction: TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden—a propensity-score matching comparative study

This article is a correction to:

  1. TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden—a propensity-score matching comparative study

    1. Read original article
Chunxue Wu&#x;Chunxue Wu1†Yunlong Dong&#x;Yunlong Dong2†Xinge LiXinge Li3Wenbo ShaoWenbo Shao1Guangshun WangGuangshun Wang2Huiyong Wu*Huiyong Wu1*Xu Chang*Xu Chang1*
  • 1Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
  • 2Department of Thoracic Surgery, Tianjin Baodi Hospital, Baodi Hospital Affiliated to Tianjin Medical University, Tianjin, China
  • 3Central Hospital Affiliated to Shandong First Medical University, Jinan, China

A Correction on
TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden—a propensity-score matching comparative study

By Wu C, Dong Y, Li X, Shao W, Wang G, Wu H and Chang X (2025) Front. Immunol. 16:1664756. doi: 10.3389/fimmu.2025.1664756

Affiliation “Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China” was erroneously given as “Shandong Tumor Hospital, Jinan, China”.

Affiliation “Department of Thoracic Surgery, Tianjin Baodi Hospital, Baodi Hospital Affiliated to Tianjin Medical University, Tianjin, China” was erroneously given as “Tianjin Baodi Hospital, Tianjin, China”.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: hepatocellular carcinoma, transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), combination therapy, high tumor burden

Citation: Wu C, Dong Y, Li X, Shao W, Wang G, Wu H and Chang X (2026) Correction: TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden—a propensity-score matching comparative study. Front. Immunol. 16:1769802. doi: 10.3389/fimmu.2025.1769802

Received: 17 December 2025; Accepted: 18 December 2025;
Published: 02 January 2026.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2026 Wu, Dong, Li, Shao, Wang, Wu and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Huiyong Wu, amluYW53aHlAMTYzLmNvbQ==; Xu Chang, Y3gxODc2OTc4NTAyM0AxNjMuY29t

†These authors share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.